↓ Skip to main content

Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial

Overview of attention for article published in BMC Cardiovascular Disorders, January 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
58 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial
Published in
BMC Cardiovascular Disorders, January 2017
DOI 10.1186/s12872-016-0464-3
Pubmed ID
Authors

Birgit Steppich, Philip Groha, Tareq Ibrahim, Heribert Schunkert, Karl-Ludwig Laugwitz, Martin Hadamitzky, Adnan Kastrati, Ilka Ott, for the Regeneration of Vital Myocardium in ST-Segment Elevation Myocardial Infarction by Erythropoietin (REVIVAL-3) Study Investigators

Abstract

Erythropoietin (EPO) has been suggested to promote cardiac repair after MI. However, the randomized, double-blind, placebo controlled REVIVAL-3 trial showed that short term high dose EPO in timely reperfused myocardium does not improve left ventricular ejection fraction after 6 months. Moreover, the study raised safety concerns due to a trend towards a higher incidence of adverse clinical events as well as a increase in neointima formation after treatment with EPO. The present study therefore aimed to assess the 5-year clinical outcomes. After successful reperfusion 138 patients with STEMI were randomly assigned to receive epoetin beta (3.33×10(4) U, n = 68) or placebo (n = 70) immediately, 24 and 48 h after percutaneous coronary intervention. The primary outcome of the present study- the combined incidence of MACE 5 years after randomization - occurred in 25% of the patients assigned to epoetin beta and 17% of the patients assigned to placebo (RR 1.5; 95% CI 0.8-3.5; p = 0.26). Target lesion revascularization was required in 15 patients (22.1%) treated with epoetin-ß and 9 patients (12.9%) treated with placebo (p = 0.15). Analysis of patients in the upper and lower quartile of baseline hemoglobin as an indirect estimate of endogenous erythropoietin levels revealed no significant impact of endogenous erythropoietin on efficiency of exogen administered epoetin-ß in terms of death and MACE. These long-term follow-up data show that epoetin beta does not improve clinical outcomes of patients with acute myocardial infarction. URL www.clinicaltrials.gov ; Unique identifier NCT00390832; trial registration date October 19th 2006.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 58 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 10%
Other 4 7%
Researcher 4 7%
Professor > Associate Professor 4 7%
Student > Doctoral Student 4 7%
Other 15 26%
Unknown 21 36%
Readers by discipline Count As %
Medicine and Dentistry 22 38%
Nursing and Health Professions 4 7%
Unspecified 2 3%
Neuroscience 2 3%
Earth and Planetary Sciences 1 2%
Other 2 3%
Unknown 25 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 January 2017.
All research outputs
#20,397,576
of 22,947,506 outputs
Outputs from BMC Cardiovascular Disorders
#1,332
of 1,625 outputs
Outputs of similar age
#353,973
of 418,332 outputs
Outputs of similar age from BMC Cardiovascular Disorders
#34
of 35 outputs
Altmetric has tracked 22,947,506 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,625 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 418,332 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.